The perfect under $10 AI stock

Forget the big cap AI stocks... this is the one to own for the next decade. [Total Wealth] BROUGHT TO YOU BY MANWARD PRESS The Perfect Under $10 AI Stock [Alex Moschina] Alex Moschina Publisher Dear Reader, If you're looking for a great AI stock under $10... you need to [watch this right away](. What the company is doing is pretty incredible. It could end up saving billions of lives... and billions of dollars. In short, the company is [the creator of the first AI-designed drug to enter clinical trials](. And this is a huge deal. Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. The Wall Street Journal reports that "the time required for the early stages of drug discovery could shrink from years to months." Not only that, it has the potential to develop "never-before-seen molecules that could treat diseases like pancreatic cancer or ALS." In short, this is groundbreaking stuff. And [this #1 AI company]( is at the forefront of all of it. The biggest pharmaceutical companies in the world are lining up to work with them. For example... - Merck is collaborating with them on three projects that could generate up to $674 million in revenue. - French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs. - Bristol Meyers Squibb signed a $1.2 billion partnership with the company. And yet... [the company I'm talking about]( is valued at just over $500 million today. And it trades for less than $10. In other words, these deals have the potential to drive the stock many times higher in the months and years ahead. So again, if you're looking for a great AI stock to own, you need to [watch this presentation right away](. [chart]( Sincerely, Alex P.S. The best way to play this AI stock involves an investment strategy used by a Kansas welder to become one of the wealthiest people in the world. [See his incredible investment approach here](. You are receiving this email because you subscribed to Total Wealth. To stop receiving special invitations and offers from Total Wealth, [click here](. Need help with your account? [Click here](. Have a question or comment for the editor? [Click here](mailto:mailbag@manwardpress.com). Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | [14 West Mount Vernon Place | Baltimore, MD 21201](#) North America: [1.800.682.5210](#) | International: [+1.443.353.4263](#) Website: [manwardpress.com]( Keep the emails you value from falling into your spam folder. [Whitelist Total Wealth](. © 2024 Manward Press, LLC | All Rights Reserved Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.